banner-no-place-nogreen.jpg

Should Canadian morning after pills carry a warning about effectiveness?

(AP Photo/Barr Pharmaceuticals Inc., File)

(AP Photo/Barr Pharmaceuticals Inc., File)

Listen

Last month the manufacturers of the European morning-after contraceptive, Norlevo, announced that their packaging would be changed to include a warning that the pill is not effective for women above 175 pounds, or 79 kilograms.

The Canadian morning after pill, Plan B, is identical to Norlevo in formulation, but does not include the warning.

Dr. Wendy Norman leads the Canadian Contraception Access Research Team, and is a family physician.

She says that, though she has questions regarding the Norlevo warning,  the scientific evidence has shown that efficacy for all types of oral contraception decreases as Body Mass Indez (BMI) increases. 

Click Listen for details.

Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Submission Policy

Note: The CBC does not necessarily endorse any of the views posted. By submitting your comments, you acknowledge that CBC has the right to reproduce, broadcast and publicize those comments or any part thereof in any manner whatsoever. Please note that comments are moderated and published according to our submission guidelines.